Skip to main content

Table 2 Management of patients who were or were not referred to cardiology

From: Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

  Cardiology referral (n = 75) No referral (n = 39) P value
Medications
 β blockers 55 (73%) 2 (5%) < 0.0001
 ACE inhibitors 66 (88%) 5 (13%) < 0.0001
 MRA 10 (13%) 1 (3%) 0.06
 Loop diuretic 21 (28%) 3 (8%) 0.01
Trastuzumab interruption 74 (99%) 35 (90%) 0.03
Trastuzumab re-started 40 (53%) 25 (64%) 0.27
Completed planned trastuzumab 26 (35%) 20 (51%) 0.09
  1. Values shown are counts (percentages). Abreviations: ACE Angiotensin converting enzyme, MRA Mineralocorticoid receptor antagonist